Pioneer in phage-based diagnostics

Twitter Youtube Linkedin Envelope
Actiphage TB awarded US Patent grant for diagnostic kit
Read more
Actiphage TB awarded US Patent grant for diagnostic kit
“Significant association between positive Actiphage test and features of progressive TB infection.”
Read more
Lancet article - PET-CT features observed following M tuberculosis exposure. biomarkers show those at high risk of TB

Actiphage – Confidence
to test for active TB

Loading...

Phage-based diagnostics

PBD Biotech specialises in the use of novel bacteriophage-based diagnostics.

The company has developed proprietary, patented technology that can be used to detect the presence of mycobacteria – the cause of tuberculosis in humans and animals – in a blood sample.

Our mission

PBD Biotech aims to drive innovation in the novel use of phages, such as Actiphage, for TB screening and drug management.

PBD Biotech developers of Actiphage TB

Contact us to discuss commercial opportunities

Latest

Loading...
Actiphage TB diagnostic releases bacterial DNA for qPCR

16 May 2023

New Centre for Phage Research features Actiphage within Innovation Showcase
May 12, 2023
The UK’s first Centre for Phage Research officially launched on 16th May 2023 and featured in the UK KTN UK Phage Innovation Showcase will be Actiphage®, a phage-based molecular diagnostic for tuberculosis.
Actiphage TB diagnostic releases bacterial DNA for qPCR

16 May 2023

New Centre for Phage Research features Actiphage within Innovation Showcase
May 12, 2023
The UK’s first Centre for Phage Research officially launched on 16th May 2023 and featured in the UK KTN UK...
1 2

developers of phage-based diagnostics

Contact Us

Registered Company Address
B4 Parkside Knowledge Gateway
Nesfield Road
Colchester
CO4 3ZL
United Kingdom

info@pbdbio.com

BIVDA member 2023
Twitter Youtube Linkedin

Privacy and cookies policy

© 2025 PBD Biotech Ltd

design: out of house